First In 10 Years, But Lenvima's First-Line Liver Label Could Be Challenged Soon
Eisai and Merck won the first US FDA approval in 10 years for a first-line hepatocellular carcinoma treatment with Lenvima, but challengers are on the horizon. The companies' recent partnership and plans for combination therapy with Keytruda may defend the drug's standing in liver cancer.
You may also be interested in...
Growing use in liver cancer drives global sales of Lenvima along with the overall performance of Eisai.
Following quickly on a Bristol trial failure with Opdivo in first-line HCC, Roche’s PD-L1 inhibitor looks poised to be the first immunotherapy approved in the setting, with plans for US, EU and China filings.
The latest drug development news and highlights from our US FDA Performance Tracker.